IVERMECTIN

Ivermectin is a macrocyclic lactone that binds glutamategated chloride channels in invertebrate nerve and muscle cells, causing paralysis and death of parasites. It is used against nematodes and ectoparasites in humans and animals. Benefits include broad antiparasitic efficacy and convenient dosing. Side effects may include dizziness, pruritus, mild GI upset, and rare neurologic reactions. Only GMP materials will be supplied, logistics all according to GDP.

Product Description


Mechanism of Action

IVERMECTIN exhibits a structured and multilayered biochemical activity profile involving modulation of enzymatic cascades, receptorbinding dynamics, intracellular signalling architecture, and metabolicflux regulation. Its molecular characteristics indicate potential interactions with catalytic pockets, allosteric surfaces, and regulatory protein domains. Through these interactions, the compound influences phosphorylation patterns, mitochondrial bioenergetics, oxidativestress networks, membrane potential stabilization, and transcriptional pathway responsiveness.

In cellular systems, mechanistic effects may include modulation of calcium flux, ROS equilibrium, structuralprotein turnover, and adaptive stressresponse activation. The compound may act as a pathway booster, suppressor, or modulator depending on dosing, cellular environment, and metabolic state.

Benefits and Advantages

This compound is widely used in biochemical, pharmacological and mechanistic research settings, including:

  • Receptorligand interaction studies and affinitymapping assays
  • Enzyme kinetics and catalyticpathway modelling
  • Mitochondrialfunction, ROSregulation and redoxbalance experiments
  • Transcriptomic, proteomic and metabolomic profiling
  • Cellstress signalling, apoptosis/autophagy pathway mapping and cytoskeletaldynamics studies
  • Pharmacodynamic simulation and SAR (structureactivity relationship) analysis

Side Effects and Risks

Risks may include unintended oxidative imbalance, mitochondrial overload, receptor crosstalk effects, disruption of ionchannel homeostasis, and dosedependent cytotoxicity. At elevated concentrations, the compound may trigger apoptosis, autophagy, or compensatory metabolic rewiring. Longterm exposure can influence transcriptional stability, signalling thresholds, and cellular resilience.

Use only in controlled laboratory environments following strict biosafety and handling protocols. Not intended for human or veterinary use.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C48H74O14

Molecular Weight

875.1 g/mol

CAS Number

71827-03-7

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Insoluble

Purity

Purity information is available upon request (COA).

Synonym

Ivermectin B1a; Dihydroavermectin B1a; 71827-03-7; 22,23-Dihydroavermectin B1a; avermectin H2B1a

IUPAC/Chemical Name

(1R,4S,5'S,6R,6'R,8R,10E,12S,13S,14E,16E,20R,21R,24S)-6'-[(2S)-butan-2-yl]-21,24-dihydroxy-12-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-5',11,13,22-tetramethylspiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2'-oxane]-2-one

InChl Key

AZSNMRSAGSSBNP-XPNPUAGNSA-N

InChl Code

InChI=1S/C48H74O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38/h12-15,19,25-26,28,30-31,33-45,49-50,52H,11,16-18,20-24H2,1-10H3/b13-12+,27-15+,32-14+/t25-,26-,28-,30-,31-,33+,34-,35-,36-,37-,38-,39-,40+,41-,42-,43+,44-,45+,47+,48+/m0/s1

References

https://pubchem.ncbi.nlm.nih.gov/compound/6321424;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download